News and reporting on cell-free DNA testing.
Natera alleges Inivata infringes its US Patent Nos. 10,262,755 and 10,597,709, which cover cancer monitoring and molecular residual disease testing.
The test will be used in the trial to improve understanding of molecular resistance mechanisms to Pfizer's Lorviqua and other ALK inhibitors.
The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.